J Korean Diabetes.  2016 Sep;17(3):168-173. 10.4093/jkd.2016.17.3.168.

Glycemic Control in Cancer Patients

• Lee KA
• Baek HS
• Park TS

• KMID: 2354281
• DOI: http://doi.org/10.4093/jkd.2016.17.3.168

Abstract

Both diabetes mellitus and cancer are common diseases whose incidence is increasing globally. Epidemiologic evidence suggests that the prevalence of cancer is increasing in diabetic patients, and both hyperglycemia and hypoglycemia may lead to poor prognosis and complications in such patients undergoing cancer therapy. Nevertheless, managing glucose in patients with diabetes and cancer can pose a significant clinical challenge. As there are no evidence-based guidelines for treating diabetes in patients with cancer, an individualized approach is required. Diabetes self-management education is a critical element of care for cancer patients with diabetes. We discuss the management of diabetes in relation to cancer surgery, chemotherapy including glucocorticoids, and enteral and parenteral nutrition. We also discuss management of hyperglycemia in patients with advanced cancer approaching end of life care.

Keyword

Diabetes mellitus; Glucocorticoids; Neoplasms; Terminal care

MeSH Terms

Diabetes Mellitus
Drug Therapy
Education
Glucocorticoids
Glucose
Humans
Hyperglycemia
Hypoglycemia
Incidence
Parenteral Nutrition
Prevalence
Prognosis
Self Care
Terminal Care
Glucocorticoids
Glucose

Reference

References

1. Ko C, Chaudhry S. The need for a multidisciplinary approach to cancer care. J Surg Res. 2002; 105:53–7.

2. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. Diabetes Care. 2010; 33:1674–85.

3. Korean Diabetes Association. Korean Diabetes Fact Sheet 2015. Seoul: Korean Diabetes Association;2015.

4. Richardson LC, Pollack LA. Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol. 2005; 2:48–53.

5. Korean Diabetes Association. Treatment guideline for diabetes. 5th ed.Seoul: Gold' Planning and Development;2015. Chapter 2, Diabetes management; p.p. 24–5.

6. American Diabetes Association. Diabetes care in the hospital. Diabetes Care. 2016; 39(Suppl 1):S99–104.

7. Flory J, Farooki A. Diabetes management in cancer patients. Oncology (Williston Park). 2016; 30:565–70.

8. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL. Postoperative mortality in cancer patients with preexisting diabetes: systematic review and metaanalysis. Diabetes Care. 2010; 33:931–9.

9. Dronge AS, Perkal MF, Kancir S, Concato J, Aslan M, Rosenthal RA. Long-term glycemic control and postoperative infectious complications. Arch Surg. 2006; 141:375–80.

10. King JT Jr, Goulet JL, Perkal MF, Rosenthal RA. Glycemic control and infections in patients with diabetes undergoing noncardiac surgery. Ann Surg. 2011; 253:158–65.

11. Koh G. Intraoperative and postoperative glycemic management in patients with diabetes. J Korean Diabetes. 2011; 12:150–53.

12. Jacob P, Chowdhury TA. Management of diabetes in patients with cancer. QJM. 2015; 108:443–8.

13. Yeh SS, Schuster MW. Megestrol acetate in cachexia and anorexia. Int J Nanomedicine. 2006; 1:411–6.

14. Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, González-González JG, Tamez-Peña AL. Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review. World J Diabetes. 2015; 6:1073–81.

15. Yates CJ, Fourlanos S, Colman PG, Cohney SJ. Divided dosing reduces prednisolone-induced hyperglycaemia and glycaemic variability: a randomized trial after kidney transplantation. Nephrol Dial Transplant. 2014; 29:698–705.

16. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009; 69:7507–11.

17. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009; 52:1766–77.

18. Psarakis HM. Clinical challenges in caring for patients with diabetes and cancer. Diabetes Spectrum. 2006; 19:157–62.

19. Fountas A, Tigas S, Giotaki Z, Petrakis D, Pentheroudakis G, Tsatsoulis A. Severe resistant hypoglycemia in a patient with a pancreatic neuroendocrine tumor on sunitinib treatment. Hormones (Athens). 2015; 14:438–41.

20. Korean Diabetes Association. Treatment guideline for diabetes. 5th ed.Seoul: Gold' Planning and Development;2015. Chapter 2, Diabetes management; p.p. 93–6.

21. Joint British Diabetes Societies (JBDS) for Inpatient Care. Glycaemic management during the inpatient enteral feeding of stroke patients with diabetes. Available from:. http://www.diabetologists-abcd.org.uk/JBDS/JBDS_IP_Enteral_Feeding_Stroke.pdf. (accessed 2014 Sep 17).

22. Korytkowski MT, Salata RJ, Koerbel GL, Selzer F, Karslioglu E, Idriss AM, Lee KK, Moser AJ, Toledo FG. Insulin therapy and glycemic control in hospitalized patients with diabetes during enteral nutrition therapy: a randomized controlled clinical trial. Diabetes Care. 2009; 32:594–6.

23. Umpierrez GE, Smiley D, Jacobs S, Peng L, Temponi A, Mulligan P, Umpierrez D, Newton C, Olson D, Rizzo M. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care. 2011; 34:256–61.

24. Korean Diabetes Association. Treatment guideline for diabetes. 5th ed.Seoul: Gold' Planning and Development;2015. Chapter 4, Special cases of diabetes; p.p. 130–3.

25. Diabetes UK. End of life diabetes care. Clinical care recommendations. 2nd ed. Available from:. http://www.diabetes.org.uk/upload/Position%20statements/End-of-life-care-Clinical-recs111113.pdf. (accessed 2014 Sep 17).

26. King EJ, Haboubi H, Evans D, Baker I, Bain SC, Stephens JW. The management of diabetes in terminal illness related to cancer. QJM. 2012; 105:3–9.

27. Zylicz Z. Management of diabetes mellitus in terminally ill cancer patients. Adv Pall Med. 2010; 9:99–102.